← boardnext 2026-09next 2028-10
VERA
Vera Therapeutics, Inc.distress 4/10 · elevated risk$35.31-2%today-37% from 52w high
Immunology / Inflammation 1Nephrology 1
Lead: IgAN · target BAFF/APRIL
Revenue
pre-revenue
Liquidity
$597M
Runway
2.0 yrs
Shares 1y
+13%
Price & events
-27.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
-9.7%
1W
-7.6%
1M
-8.0%
3M
-25.6%
6M
+56.1%
1Y
+0.7%
2Y
+100.7%
5Y
+207.1%
All
Overview
- Market Cap
- $2.54B
- Enterprise Value
- $2.50B
- Volume
- 75.96K
- 52 Week Range
- $19.25 – $55.67
- Total Shares
- 71.78M
- Float Shares
- 51.95M
- Short %
- 21.45%
- % Held by Insiders
- 0.78%
- % Held by Institutions
- 110.63%
- RVOL
- 0.04x
- Beta
- 0.92
Pipeline stages · 2 programs
Atacicept 150 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VGA039
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Ataciceptbreakthrough | IgA Nephropathy (IgAN), Berger Disease | — | active not recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | Ataciceptbreakthrough | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-12-15 | Phase 3 | VGA039 | Von Willebrand Disease (VWD) | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-01-15 | Phase 1/2 | VGA039 | Von Willebrand Diseases | — | recruiting |
| 2031-05-21 Estimated 50% readout ~2031-07-05 | Phase 2 | Atacicept 150 mgbreakthrough | IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease | — | enrolling by invitation |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 10
- 2026Guided 40%PDUFAPDUFAatacicept · Anticipated PDUFA date if Phase 3 successfulSEC 8-K
- fourth quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)atacicept · Submit sBLA for full approvalSEC 8-K
- third quarter of 2026Guided 70%readoutatacicept · ORIGIN 3 eGFR resultsSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-02fda agreementatacicept · FDA aligned on revised earlier ORIGIN 3 eGFR analysis plan to support full approvalSEC 8-K
- 2025trial initiationsecondaryatacicept · PIONEER studySEC 8-K
- fourth quarter of 2025regulatory submissionFiled (NDA/BLA)atacicept · Plan to submit BLA for accelerated approval to FDASEC 8-K
- second quarter of 2025readoutPhase 3atacicept · Topline results from Phase 3 ORIGIN 3 trialSEC 8-K
- Q4 2024trial initiationsecondaryatacicept · ORIGIN Extend study providing extended accessSEC 8-K
- American Society of Nephrology Kidney Week 2024conferencedata presentationsecondaryPhase 2atacicept · 96-week data from Phase 2b ORIGIN studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $82 (+132% upside) · 14 analysts
- 2026-07-08HC Wainwright & Co.Buy
- 2026-07-08WedbushNeutral
- 2026-07-08TD CowenBuy
- 2026-07-08GuggenheimBuy
- 2026-07-07B of A SecuritiesBuy
- 2026-05-15Evercore ISI GroupOutperform
Competitors — BAFF/APRIL
- VORVor Biopharma Inc.$1.0B · D2
Recent news
- 2026-07-23Price to book forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
- 2026-07-22Vera Therapeutics (VERA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
- 2026-07-22(VERA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
- 2026-07-21Vera Therapeutics (VERA) TD Cowen 46th Annual Health Care Conference Summary - Quartr
- 2026-07-21Price to earnings forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
- 2026-07-17The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why - Sahm
- 2026-07-16Enterprise value to revenue forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
- 2026-07-14Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.